KR20220023340A - mRNA 제형 - Google Patents
mRNA 제형 Download PDFInfo
- Publication number
- KR20220023340A KR20220023340A KR1020217038364A KR20217038364A KR20220023340A KR 20220023340 A KR20220023340 A KR 20220023340A KR 1020217038364 A KR1020217038364 A KR 1020217038364A KR 20217038364 A KR20217038364 A KR 20217038364A KR 20220023340 A KR20220023340 A KR 20220023340A
- Authority
- KR
- South Korea
- Prior art keywords
- mrna
- pseudouridine
- combination
- thio
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19171323 | 2019-04-26 | ||
| EP19171323.9 | 2019-04-26 | ||
| PCT/EP2020/061477 WO2020216911A1 (en) | 2019-04-26 | 2020-04-24 | Mrna formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220023340A true KR20220023340A (ko) | 2022-03-02 |
Family
ID=66290283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217038364A Pending KR20220023340A (ko) | 2019-04-26 | 2020-04-24 | mRNA 제형 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220362360A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3958893A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7650001B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220023340A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114096272B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020263948B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021021262A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3138011A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL287560B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021013018A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202111720TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020216911A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7496623B2 (ja) * | 2019-01-04 | 2024-06-07 | イーザアールエヌーエー イムノセラピーズ エンヴェー | mRNAワクチン |
| US20220143161A1 (en) * | 2019-03-13 | 2022-05-12 | Etherna Immunotherapies Nv | Mrna vaccine |
| CN119701015A (zh) * | 2023-09-26 | 2025-03-28 | 深圳瑞吉生物科技有限公司 | 一种细胞因子mRNA组合药物及其应用 |
| CN121873266A (zh) * | 2026-03-18 | 2026-04-17 | 北京悦康科创医药科技股份有限公司 | 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2201100E (pt) * | 2007-09-14 | 2016-06-03 | Univ Brussel Vrije | Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação |
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| US9408909B2 (en) * | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
| EP3173474A1 (en) * | 2007-09-14 | 2017-05-31 | Vrije Universiteit Brussel | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| WO2015071295A1 (en) | 2013-11-12 | 2015-05-21 | Vrije Universiteit Brussel | Rna transcription vector and uses thereof |
| DK4276189T3 (da) * | 2015-09-21 | 2026-05-26 | Trilink Biotechnologies Llc | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| MA47515A (fr) * | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
-
2020
- 2020-04-24 US US17/604,559 patent/US20220362360A1/en active Pending
- 2020-04-24 CN CN202080038101.1A patent/CN114096272B/zh active Active
- 2020-04-24 JP JP2021563262A patent/JP7650001B2/ja active Active
- 2020-04-24 CA CA3138011A patent/CA3138011A1/en active Pending
- 2020-04-24 WO PCT/EP2020/061477 patent/WO2020216911A1/en not_active Ceased
- 2020-04-24 KR KR1020217038364A patent/KR20220023340A/ko active Pending
- 2020-04-24 AU AU2020263948A patent/AU2020263948B2/en active Active
- 2020-04-24 MX MX2021013018A patent/MX2021013018A/es unknown
- 2020-04-24 EP EP20721229.1A patent/EP3958893A1/en active Pending
- 2020-04-24 BR BR112021021262A patent/BR112021021262A2/pt unknown
- 2020-04-24 SG SG11202111720TA patent/SG11202111720TA/en unknown
- 2020-04-24 IL IL287560A patent/IL287560B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021021262A2 (pt) | 2021-12-21 |
| SG11202111720TA (en) | 2021-11-29 |
| AU2020263948B2 (en) | 2026-06-25 |
| CN114096272B (zh) | 2024-08-06 |
| EP3958893A1 (en) | 2022-03-02 |
| CN114096272A (zh) | 2022-02-25 |
| WO2020216911A1 (en) | 2020-10-29 |
| JP7650001B2 (ja) | 2025-03-24 |
| IL287560B2 (en) | 2026-02-01 |
| US20220362360A1 (en) | 2022-11-17 |
| AU2020263948A1 (en) | 2021-12-23 |
| MX2021013018A (es) | 2022-03-11 |
| CA3138011A1 (en) | 2020-10-29 |
| IL287560B1 (en) | 2025-10-01 |
| JP2022532038A (ja) | 2022-07-13 |
| IL287560A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7650001B2 (ja) | mRNA製剤 | |
| Kottke et al. | Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer | |
| Franzusoff et al. | Yeasts encoding tumour antigens in cancer immunotherapy | |
| TW202003032A (zh) | 包含s t i n g 促效劑之胞外囊泡 | |
| JP2019515900A (ja) | がんを処置するためのToll様レセプター9アゴニストおよび腫瘍抗原を含む粒子の腫瘍内送達 | |
| US20250041394A1 (en) | Immunostimulatory mrna compositions and uses thereof | |
| KR20240134324A (ko) | mRNA 치료 조성물 | |
| US20240102047A1 (en) | An oncolytic virus vector coding for variant interleukin-2 (vIL-2) polypeptide | |
| CN116113422A (zh) | 免疫细胞的mRNA转染 | |
| KR20170100033A (ko) | 분지형 및 선형 키메라 화합물, 폴리뉴클레오티드, 그것들의 용도 및 제조 방법 | |
| AU2021347807A9 (en) | Improved methods and compositions for expression of nucleic acids in cells | |
| KR20220094221A (ko) | 종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀 | |
| JP6273290B2 (ja) | 疾患の処置のための同種異系のオートファゴソーム強化組成物 | |
| Su et al. | Immune‐check blocking combination multiple cytokines shown curative potential in mice tumor model | |
| JP2026512425A (ja) | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 | |
| US20200038496A1 (en) | Novel vegfr-2 targeting immunotherapy approach | |
| WO2021074648A1 (en) | Vector for cancer treatment | |
| JP2023502925A (ja) | 生体内遺伝子治療のためのポリマー封入ウイルスベクター | |
| HK40068420A (en) | Mrna formulation | |
| HK40068420B (en) | Mrna formulation | |
| Jeon | Role of toll-like receptor agonists as cancer vaccine adjuvants | |
| JP2025508829A (ja) | 負に帯電した粒子による固形腫瘍の治療 | |
| CN122057015A (zh) | 基于肿瘤特异性抗原的细胞治疗制剂及其在实体瘤中的应用 | |
| Pulakkat et al. | Immunogene Therapy in Cancer | |
| Parikh et al. | Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |